MIcrovascularizED Tumour on chip for Cellular ImagiNg of Drug Response and Cell...
MIcrovascularizED Tumour on chip for Cellular ImagiNg of Drug Response and Cell moTility
MImETIC INDiRECT aims to develop a standardised, accessible, versatile organ-on-chip toolkit for cancer biology and drug discovery research, compatible with microscopy-based (live imaging and confocal) techniques. The project is e...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PID2021-126523OB-I00
DESARROLLO DE UN MODELO TRIDIMENSIONAL DE MELANOMA DINAMICO,...
115K€
Cerrado
MTOAC
Multi compartmental Tumor on a Chip
185K€
Cerrado
SeCtOR ENABleRs
Standard Collagenous ORgans on chip ENvisaging Advanced Biol...
185K€
Cerrado
3DCanPredict
Predicting clinical response to anticancer drugs using 3D bi...
150K€
Cerrado
DPI2012-38090-C03-02
APROXIMACION DE ALTO RENDIMIENTO A LA CUANTIFICACION POR IMA...
64K€
Cerrado
PID2021-122409OB-C22
ANALISIS CUANTITATIVO DE ORGANOIDES DERIVADOS DE PACIENTES D...
145K€
Cerrado
Información proyecto MImETIC INDiRECT
Duración del proyecto: 27 meses
Fecha Inicio: 2019-04-15
Fecha Fin: 2021-07-31
Líder del proyecto
CHERRY BIOTECH
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
197K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
MImETIC INDiRECT aims to develop a standardised, accessible, versatile organ-on-chip toolkit for cancer biology and drug discovery research, compatible with microscopy-based (live imaging and confocal) techniques. The project is expected to facilitate academia and industry adoption of microfluidic 3D cell culture systems for comparable and reproducible results in a complex biomimetic animal free model for cancer drug discovery, toxicology, advanced (pre)clinical as well as personalized medicine. The toolkit components will consist of an integrated temperature controller dual-chamber chip, the Cherry Biotech CubiX system and growth factor optimized collagenous solutions for each chip chamber. The dual chamber chip, with cellular migration lanes, will have two tailored collagen-based formulations, designed per chamber. The CubiX platform is a compact flow and temperature controller, allowing optional sensor (e.g. O2) integration, compatible with single chips or 24-well plates. The cancer(s) sub-types to be used toolkit standardization will be dictated by market needs, where commercial cell lines (cancerous and non-cancerous) will be used to create the microvascularized complex tissue model. Potential project risks have been identified with appropriate mitigation strategies, where the project promotes adoption of standardized, cost-effective and versatile cancer organ-on-chip platforms in the market, rather than disruptive academic findings. Access of the aforementioned system to a worldwide growth market will fully exploit the project results, disseminated by direct and indirect marketing and scientific approaches. Project implementation will be an academic-industry collaborative and multidisciplinary manner providing the acquisition of diverse and unconventional complementary skills, leading to an understanding of both sectors requirements. We envision the above-mentioned to facilitate future academic and industry collaborations.